In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines Inc's commitment to precision oncology positions it at the forefront of targeted cancer therapies.

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

With that, I’ll turn the call over to Dr. Mark Goldsmith, Revolution Medicines’ Chairman and Chief Executive Officer. Mark? Thanks, Ryan. It’s good to be with you this afternoon. At ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.66% ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...

Additionally, a replay of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference. About ...

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its ...